<DOC>
	<DOCNO>NCT01897610</DOCNO>
	<brief_summary>`` Immuncell-LC '' aspect therapeutic efficacy safety administer Nexavar advance Hepatocellular carcinoma patient compare control group receive administration drug .</brief_summary>
	<brief_title>Efficacy Safety 'Immuncell-LC Group ' 'Non-treatment Group ' Nexavar Treated Patients Advanced Hcc</brief_title>
	<detailed_description>- primary outcome Compare clinical efficacy group treat cell therapeutic Immuncell-LC evaluate progression free survival untreated group - secondary outcome compare clinical efficacy group treat Immuncell-LC , drug treating advance hepatocellular carcinoma evaluate overall survival , disease control rate , change Alpha Feto Protein ( AFP ) figure baseline last observation date untreated group evaluate adverse reaction , clinical pathological test safety .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients consent study provide signature self , guardian legal representative The patient 20 less 80 year old The patient diagnose hepatocellular carcinoma pathological/radiological test stage III IV ChildPugh Score A ECOG Performance Status ( ECOGPS ) less 2 equal Patients receive ready Nexavar treatment Patients satisfy follow condition blood test kidney function test Absolute granulocyte count big 1,000/ÂµL Hemoglobin big 8.5 g/dL Platelet count big 5x10^10/L Blood Urea Nitrogen ( BUN ) Creatinine 1.5xupper normal limit Patients immune deficient history autoimmune disease ( Ex . Rheumatoid Arthritism , Systemic Lupus Erythematosus , Vasculitis , Multiple sclerosis , Adolescent InsulinDependent Diabetes Mellitus , etc . ) Patients history malignant tumor recent 5 year prior study exception basal cell carcinoma , local prostate cancer , cervical cancer , liver cancer . Patients anticancer medication study exception Nexavar Patients serious dysfunction organ subinvestigator 's opinion Patients serious allergichistory subinvestigator 's opinion Patients serious mental disease subinvestigator 's opinion Pregnant woman , nurse mother intention pregnant study Patients participate clinical trial within 4 week study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Immuncell-LC , advance hepatocellular carcinoma</keyword>
</DOC>